Brazil's National Health Surveillance Agency (ANVISA) said on Wednesday that a volunteer in a clinical trial of the COVID-19 vaccine developed by AstraZeneca and Oxford University has died, stating it had received data from an investigation into the matter.
"None of the trials now under way are created to detect a reduction in any serious outcome such as hospitalisations, intensive care use, or deaths".
He explained that all ongoing phase three trials for which details have been released are evaluating mild, not severe, disease - and they will be able to report final results once around 150 participants develop symptoms. "Nor are the vaccines being studied to determine whether they can interrupt transmission of the virus".
AstraZeneca announced in early September that its coronavirus vaccine candidate AZD1222 was moving into phase three clinical trials in the USA, with about 30,000 participants. The same is true of its ability to save lives or prevent transmission: "the trials are not created to find out".
The U.K.'s Medicines and Healthcare products Regulatory Agency determined that the evidence was insufficient to link AstraZeneca's U.K trial program setback with the vaccine, as per Reuters. They're "event-driven" trials, meaning that the goal is to keep them going until a certain number of volunteers become infected.
It's not clear yet whether the late participant was receiving the vaccine or placebo.
Microsoft launches into space
Thanks to the power of Azure, the emulator will generate the operation of an entire network of satellites. Most big tech companies are directly/indirectly involved in the private space sector, albeit Microsoft.
How Arsenal Transfer News Affect Their Odds to Win?
Other players rumored to be destined for Arsenal include; Sokratis Papastathopoulos, from Borussia Dortmund, and Saul Niguez. . If they are rumored to buy an elite player, during the transfer window, they play well which increases the odds of winning.